Patent ID: 11866502
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 50:
51. A method of treating a cancer, reducing tumor growth, and/or causing tumor regression in a subject, the method comprising administering to a subject in need thereof an antibody-drug conjugate (ADC) comprising an anti-FGFR2 antibody or antigen-binding fragment thereof and a cytotoxin, wherein the anti-FGFR2 antibody or antigen-binding fragment thereof comprises:
(i) an HCDR1 having the amino acid sequence of SEQ ID NO: 4; an HCDR2 having the amino acid sequence of SEQ ID NO: 6; an HCDR3 having the amino acid sequence of SEQ ID NO: 8; an LCDR1 having the amino acid sequence of SEQ ID NO: 12; an LCDR2 having the amino acid sequence of SEQ ID NO: 14; and an LCDR3 having the amino acid sequence of SEQ ID NO: 16; or
(ii) an HCDR1 having the amino acid sequence of SEQ ID NO: 24; an HCDR2 having the amino acid sequence of SEQ ID NO: 6; an HCDR3 having the amino acid sequence of SEQ ID NO: 26; an LCDR1 having the amino acid sequence of SEQ ID NO: 30; an LCDR2 having the amino acid sequence of SEQ ID NO: 32; and an LCDR3 having the amino acid sequence of SEQ ID NO: 34.